Cholecalciferol (Vitamin D) Intervention to Prevent Respiratory Infection Study

A double-blind randomised controlled trial to evaluate the efficacy of 20,000 IU/wk cholecalciferol in reducing respiratory tract infection in a cohort of healthy young adults

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12612000054819

Acronym

CIPRIS

Enrollment

Registered

2012-01-11

Start date

2012-04-15

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study will evaluate the efficacy of 20,000 IU/week cholecalciferol supplementation relative to placebo in reducing the frequency of clinically-verified acute respiratory tract infections in a cohort of young adults in Tasmania.

Interventions

Cholecalciferol (20,000 IU oral capsule/week) for 17 weeks.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

Students undertaking study at the MS1 building of University of Tasmania Medical Sciences Precinct (17 Liverpool St Hobart TAS) for the full duration between May and September 2012

Exclusion criteria

-Persons who have used tobacco within the 6 months preceding study entry -Persons who have used any vitamin D (cholecalciferol or ergocalciferol) supplements or calcium supplements within the 3 months preceding study entry and/or persons who refuse to not start taking any such supplement during the study -Persons using any immunomodulatory medication, diuretic medication, antiepileptic medication, or barbiturates. -Persons who presently have been diagnosed with any chronic infectious disease (e.g. HIV, tuberculosis), chronic immune deficiency or autoimmune condition, or respiratory condition (e.g. asthma, chronic obstructive pulmonary disease). -Persons who are hypersensitive to vitamin D.

Outcome results